Table 1.
Descriptive characteristics of included studies.
| Lead author | Year | Country | Vaccine | Study type | Source of cost estimation | Primary data on resource utilisation | Ingredients based approach | Vaccine delivery during routine ANC visit? |
|---|---|---|---|---|---|---|---|---|
| Atkins | 2016 | USA | Tdap | EE | Literature | Not specified | ||
| Baguelin | 2010 | UK | Influenza | EE | Government tariff | Not specified | ||
| Berman | 1991 | Indonesia | TT | EE | Primary data | X | X | Yes |
| Fernández-Cano | 2015 | Spain | Tdap | EE | Government tariff | Not specified | ||
| Garcia | 2016 | Spain | Influenza | EE | Government tariff | Not specified | ||
| Giorgakoudi | 2018 | UK | GBS | EE | Government tariff | Not specified | ||
| Jit | 2010 | UK | Influenza | EE | Government tariff + secondary data | Not specified | ||
| Kim | 2014 | South Africa | GBS | EE | Secondary data + expert opinion | X | Yes | |
| Kim | 2017 | USA | GBS | EE | Secondary data + expert opinion | X | Yes | |
| Pecenka | 2017 | Malawi | Influenza | Cost study | Primary + secondary data | X | X | Yes |
| Sartori | 2016 | Brazil | Tdap | EE | Secondary data | X | Yes | |
| Skedgel | 2011 | Canada | Influenza | EE | Government tariff / unpublished estimatea | Not specified | ||
| Terranella | 2013 | USA | Tdap | EE | Assumption | Not specified | ||
| van Hoek | 2016 | UK | Tdap | EE | Assumption | Not specified | ||
| Xu | 2016 | USA | Influenza | EE | Literature | Yes | ||
| Zhao | 2016 | China | Hepatitis E | EE | Literature | Not specified |
EE = Economic Evaluation; TT = Tetanus Toxoid; Tdap = Tetanus, diphtheria & acellular pertussis
a
Private communication from Nova Scotia Department of Health Promotion and Protection.